TY - JOUR
T1 - Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease
AU - Maruyama, Masahiro
AU - Arai, Hiroyuki
AU - Sugita, Mitsunori
AU - Tanji, Haruko
AU - Higuchi, Makoto
AU - Okamura, Nobuyuki
AU - Matsui, Toshifumi
AU - Higuchi, Susumu
AU - Matsushita, Sachio
AU - Yoshida, Hiroshi
AU - Sasaki, Hidetada
PY - 2001
Y1 - 2001
N2 - Cerebrospinal fluid (CSF) levels of amyloid β-protein ending at amino acid position 42 (CSF-A β1-42) and CSF-tau levels were quantified by sandwich ELISAs in 19 patients with mild cognitive impairment (MCI) who eventually developed Alzheimer's disease (AD) on follow-up as well as in 15 age-matched normal controls and 54 AD patients at diverse stages of the disease. In the present study, the annual conversion rate was approximately 15%. The CSF-A β1-42 levels did not differ significantly between the normal control group and the MCI group, however, these values declined significantly once AD became clinically overt. In contrast to CSF-A β1-42, CSF-tau levels were significantly increased in the MCI stage, and these values continued to be elevated thereafter, indicating that increased levels of CSF-tau may help in detecting MCI subjects who are predicted to develop AD. We propose that CSF-tau and CSF-A β1-42 must be used as two distinct biomarkers that should be applied appropriately in clinical settings.
AB - Cerebrospinal fluid (CSF) levels of amyloid β-protein ending at amino acid position 42 (CSF-A β1-42) and CSF-tau levels were quantified by sandwich ELISAs in 19 patients with mild cognitive impairment (MCI) who eventually developed Alzheimer's disease (AD) on follow-up as well as in 15 age-matched normal controls and 54 AD patients at diverse stages of the disease. In the present study, the annual conversion rate was approximately 15%. The CSF-A β1-42 levels did not differ significantly between the normal control group and the MCI group, however, these values declined significantly once AD became clinically overt. In contrast to CSF-A β1-42, CSF-tau levels were significantly increased in the MCI stage, and these values continued to be elevated thereafter, indicating that increased levels of CSF-tau may help in detecting MCI subjects who are predicted to develop AD. We propose that CSF-tau and CSF-A β1-42 must be used as two distinct biomarkers that should be applied appropriately in clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=0035693097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035693097&partnerID=8YFLogxK
U2 - 10.1006/exnr.2001.7814
DO - 10.1006/exnr.2001.7814
M3 - Article
C2 - 11716567
AN - SCOPUS:0035693097
SN - 0014-4886
VL - 172
SP - 433
EP - 436
JO - Experimental Neurology
JF - Experimental Neurology
IS - 2
ER -